Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)

Journal:

Nature Communications

Published:

2025-11-03

DOI:

10.1038/s41467-025-64660-z

Affiliations:

15

Authors:

33

Go to article

Institutions	Authors	Share
Fujian Cancer Hospital, China	20.000000 20.000000 20.000000	0.61
Fujian Medical University, China	5.000000	0.15
Hengrui, China	3.000000	0.09
The Hospital of Nanan City, China	2.000000	0.06
No.2 Hospital of Longhai City, China	1.000000	0.03
Zhangzhou Municipal Hospital of Fujian Province, China	1.000000	0.03
Heping Hospital Affiliated to Changzhi Medical College, China	1.000000	0.03

Interested in Oncology and Carcinogenesis?